Anti-PD-1/PD-L1 immunotherapy was recently approved as one of the first-line approaches for esophageal carcinoma, but the poor response rate of 10–30% in patients with ESCC indicates that only a small group of patients will benefit from anti-PD-1/PD-L126. Here, CD274 is linked to esophageal squamous cell carcinoma.